PIK3CA and neoplasm: Moreover, pre-clinical data demonstrates the improved anti-tumor effect of the combination PI3K inhibitor and immunotherapy.41 However, it remains unknown whether multi-hit PIK3CA tumors that are TMB high and/or are MSI-high are driven by the PIK3CA mutations or are primarily passenger mutations driven by high TMB.